Wilate

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Hemophilia aConcentration

35 competitors in Hemophilia a

#DrugCompanyPhaseTrials

1

Hemlibra

Roche

Approved

162

Rayos

RRoxane Laboratories

Approved

13

Cyklokapron

JJ Molner

Approved

—4

Efanesoctocog Alfa

Sanofi

Phase 3

75

Advate

Takeda

Phase 3

46

Marstacimab

Pfizer

Phase 3

17

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

18

Rfviia

Roche

Phase 3

29

PF-06741086

Pfizer

Phase 3

210

Wilate

Octapharma

Phase 3

1Show 10 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Von Willebrand disease1 trial

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

Completed·Octapharma·Phase 3·NCT04953884·12 enrolled

Concentration1 trial

Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT04555785·120 enrolled

Efficacy and Safety1 trial

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Completed·Octapharma·Phase 3·NCT04052698·43 enrolled

Severe Hemophilia a1 trial

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Completed·Octapharma·Phase 3·NCT02954575·57 enrolled

Immunogenicity1 trial

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Completed·Octapharma·Phase 3·NCT03376516·11 enrolled

Details

Drug Info

Related News